Critical Outcome Technologies Inc. Announces The Launch Of A Drug Discovery Program For Alzheimer's Disease
Critical Outcome Technologies Inc. (COTI)(TSX VENTURE:COT), announced that the Company has undertaken the discovery and optimization of novel lead compounds for the treatment of Alzheimer"s Disease (AD). "Based on partnering interest expressed by multiple global pharmaceutical organizations we have decided to establish a drug discovery program to help combat this devastating disease", said Mr. Michael Cloutier, Chief Executive Officer of COTI.
Cardiovascular